Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Gilead Sciences, Inc.    GILD   US3755581036

GILEAD SCIENCES, INC. (GILD)

233
SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 

Gilead 1Q Net Slips 32% On Higher Expenses, Weaker Margins

04/26/2012 | 04:54pm US/Eastern
Recommend:
0

Gilead Sciences Inc. (>> Gilead Sciences, Inc.) first-quarter earnings slid 32% as the biopharmaceutical company reported higher expenses and weaker margins, though adjusted profits improved.

Product sales, which generate the majority of the company's revenue, have been rising steadily in recent quarters. In the latest period, product sales rose 19%. Sales of antiviral products, its dominant revenue stream, increased 18 as HIV drugs Atripla and Truvada saw sales gains of 19% and 13%, respectively.

The company also receives royalties for Tamiflu from Roche Holding AG (RHHBY, ROG.VX). Royalty, contract and other revenue from collaborations were also up 19% last quarter.

Lately, Gilead has been focusing on simplifying HIV therapy, a treatment market that it dominates. In December, U.S. regulators accepted Gilead's new drug application for its Quad combination HIV drug, which analysts view as a potential growth driver. The Food and Drug Administration in February also granted Truvada a priority-review schedule, advancing what could become the first treatment labeled for HIV prevention.

Earlier this year, Gilead bought Pharmasset Inc. for more than $11 billion in a deal expected to accelerate the development of treatments for hepatitis C, a hotly contested market. A key drug candidate it obtained with Pharmasset, GS-7977, suffered a setback in February as a majority of hepatitis-C patients in one arm of a clinical trial had a relapse, raising questions about the drug's potential.

In the latest quarter, Gilead posted a profit of $442 million, or 57 cents a share, down from $651.1 million, or 80 cents a share, a year earlier. Excluding acquisition-related expenses, restructuring and stock-based compensation, earnings rose to 91 cents from 87 cents.

Revenue gained 19% to $2.28 billion.

Analysts polled by Thomson Reuters had expected a profit of 93 cents a share and revenue of $2.2 billion.

Operating margin narrowed to 35.1% from 46.8% as total costs and expenses jumped 45%.

Shares were down 1.4% to $52 after-hours. Through the close, the stock is up 29% since the start of the year.

 
   -By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com 

Stocks mentioned in the article : Gilead Sciences, Inc.
Recommend :
0
React to this article
Latest news on GILEAD SCIENCES, INC.
1d ago GILEAD SCIENCES : Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosci..
1d ago GILEAD SCIENCES : Signs Pact with Medicines Patent Pool
2d ago GILEAD SCIENCES : U.S. Food and Drug Administration Approves Gilead's Zydelig® i..
2d ago GILEAD SCIENCES : Announces New Agreement with Medicines Patent Pool for Access ..
2d ago GILEAD SCIENCES : Inks Agreement with Medicines Patent Pool
3d ago GILEAD SCIENCES : Hepatitis C medicine being imported for Rs 1 crore
3d ago A mixed quarter for bets on U.S. stock volatility
3d ago GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead's Zydelig for..
4d ago GILEAD SCIENCES : Pricey Drug for Hepatitis C Brings Loud Criticism from Activis..
4d ago GILEAD SCIENCES : Announces New Agreement with Medicines Patent Pool for Access ..
Advertisement
Chart
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Income Statement Evolution
Gilead Sciences, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF